Finance

Lists
Why is 326030 up 3,41%?
Dive Deeper
326030:KRX
SK Biopharmaceuticals Co Ltd
75 800,00 KRW
+3,41%
(+2 500,00) 1D
19 ოქტ, 15:19:57 GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 326030...
Open
73 100 KRW
High
76 400 KRW
Low
72 400 KRW
Mkt. cap
5,94 ტრლ.
Avg. vol.
109,14 ათ.
Volume
76,56 ათ.
P/E ratio
14,80
52-wk high
144 100 KRW
52-wk low
67 800 KRW
EPS
5 120 KRW
Shares outstanding
78,31 მლნ.
No. of employees
246
Open
73 100 KRW
High
76 400 KRW
Low
72 400 KRW
Mkt. cap
5,94 ტრლ.
Avg. vol.
109,14 ათ.
Volume
76,56 ათ.
P/E ratio
14,80
52-wk high
144 100 KRW
52-wk low
67 800 KRW
EPS
5 120 KRW
Shares outstanding
78,31 მლნ.
No. of employees
246
News stories
From web sources and news partners
About SK Biopharmaceuticals Co Ltd
CEO-
Employees246
Founded1993
Headquarters-
SectorPharmaceutical industry
Websiteskbp.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
191,73 მლრ.
194,36 მლრ.
227,89 მლრ.
247,37 მლრ.
Cost of goods sold
7,55 მლრდ.
14,95 მლრდ.
14,33 მლრდ.
15,02 მლრდ.
Cost of revenue
7,55 მლრდ.
14,95 მლრდ.
14,33 მლრდ.
15,02 მლრდ.
Research and development expenses
40,93 მლრდ.
51,85 მლრდ.
47,59 მლრდ.
49,66 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
68,98 მლრდ.
77,42 მლრდ.
71,09 მლრდ.
81,28 მლრდ.
Operating expense
114,07 მლრ.
133,13 მლრ.
123,79 მლრ.
135,29 მლრ.
Total operating expenses
121,62 მლრ.
148,08 მლრ.
138,12 მლრ.
150,30 მლრ.
Operating income
70,11 მლრდ.
46,28 მლრდ.
89,77 მლრდ.
97,06 მლრდ.
Other non operating income
-8,46 მლრდ.
-7,51 მლრდ.
-5,78 მლრდ.
-5,76 მლრდ.
EBT including unusual items
62,11 მლრდ.
33,76 მლრდ.
99,98 მლრდ.
93,36 მლრდ.
EBT excluding unusual items
61,27 მლრდ.
36,66 მლრდ.
89,89 მლრდ.
89,81 მლრდ.
Income tax expense
-9,26 მლრდ.
-98,98 მლრდ.
-2,76 მლრდ.
8,30 მლრდ.
Effective tax rate
-14,90%
-293,19%
-2,76%
8,88%
Other operating expenses
1,37 მლრდ.
1,11 მლრდ.
2,22 მლრდ.
1,42 მლრდ.
Net income
74,14 მლრდ.
136,59 მლრ.
105,16 მლრ.
85,06 მლრდ.
Net profit margin
38,67%
70,28%
46,15%
34,39%
Earnings per share
-
-
-
-
Interest and investment income
1,88 მლრდ.
1,72 მლრდ.
1,68 მლრდ.
2,37 მლრდ.
Interest expense
-1,70 მლრდ.
-1,32 მლრდ.
-1,30 მლრდ.
-1,26 მლრდ.
Net interest expenses
179,24 მლნ.
397,10 მლნ.
380,91 მლნ.
1,11 მლრდ.
Depreciation and amortization charges
2,23 მლრდ.
2,18 მლრდ.
2,19 მლრდ.
2,17 მლრდ.
EBITDA
74,11 მლრდ.
50,23 მლრდ.
93,70 მლრდ.
101,08 მლრ.
Gain or loss from assets sale
10,55 მლნ.
176,00 მლნ.
-
1,00 ათ.
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები